GlassScriptPhysician profile
Pradeep K Bhat
NPI 1275729592
$10,260.76
in general payments reported to CMS, 2019-2025
39 companies · $1,403 in 2025
The $1,403 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,596 · 2020: $1,147 · 2021: $883 · 2022: $1,783 · 2023: $1,848 · 2024: $1,601 · 2025: $1,403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,851.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,158.09 | 2020-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,091.92 | 2019-2025 | Lifevest |
| Amgen INC. | $1,012.38 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $942.65 | 2019-2023 | Jeti |
| Pfizer INC. | $657.86 | 2019-2025 | |
| Biosense Webster, INC. | $598.33 | 2019-2020 | |
| Edwards Lifesciences Corporation | $545.24 | 2020-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $491.63 | 2023-2024 | Micra, Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $433.78 | 2019-2024 | Xarelto |
| Inari Medical, INC. | $329.00 | 2021 | |
| Novo Nordisk INC | $292.80 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Impulse Dynamics (USA) INC. | $290.43 | 2022-2024 | Optimizer, Optimizer |
| E.R. Squibb & Sons, L.L.C. | $288.97 | 2020-2025 | Eliquis, Camzyos |
| Abiomed | $284.64 | 2023-2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.34 | 2019-2025 | Jardiance |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $228.03 | 2019-2024 | Farxiga |
| Cleerly, INC. | $180.33 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Merck Sharp & Dohme LLC | $128.81 | 2022-2025 | Verquvo, Capvaxive |
| Medtronic Vascular, INC. | $117.82 | 2020 | |
| Alnylam Pharmaceuticals INC. | $114.18 | 2020-2025 | Amvuttra |
| Cvrx, INC. | $96.04 | 2022 | |
| Kestra Medical Technology Services, INC. | $95.26 | 2024-2025 | Assure Wcd |
| Amarin Pharma, INC. | $91.31 | 2019-2020 | |
| Bardy Diagnostics, INC. | $85.00 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $55.52 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Boston Scientific Corporation | $50.00 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $45.34 | 2024 | Arcalyst |
| Tactile Systems Technology INC | $40.61 | 2020-2023 | Entre Plus, Flexitouch Plus |
| Lexicon Pharmaceuticals, INC. | $37.63 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $33.21 | 2019-2021 | |
| Esperion Therapeutics, INC. | $32.51 | 2020-2022 | |
| Daiichi Sankyo INC. | $28.10 | 2023 | Injectafer |
| Glaxosmithkline, LLC. | $26.30 | 2025 | Arexvy, Shingrix |
| Akcea Therapeutics, INC. | $23.38 | 2019 | |
| Medicomp INC | $21.01 | 2023 | Telepatch Cardiac Monitor |
| Kiniksa Pharmaceuticals, LTD. | $20.16 | 2023 | Arcalyst |
| Lilly USA, LLC | $17.94 | 2025 | Zepbound |
| Scpharmaceuticals INC. | $14.44 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeep Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.